Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Obesity Companies Prolong The Inevitable As Cash Runs Out

Executive Summary

Arena and Vivus both announce efforts to conserve cash and they struggle with virtually nonexistent sales of their obesity drugs. Neither company has laid out plans for next steps.

You may also be interested in...



Q1 Earnings In Brief: Ironwood, Incyte, Arena, Ariad

Earnings season continues with reports from a swath of small biotechs. Ironwood reports higher Linzess sales, Incyte makes a European acquisition, Arena continues its decline, and Ariad explores strategic options.

Obesity By The Numbers

Obesity is one of the most prevalent diseases in the US, according to CDC, which estimates that about one-third of Americans, or 76 million adults, are obese. Obesity leads to other chronic conditions like diabetes, heart disease and some cancers. Yet, patients and physicians have been slow to turn to drugs for treatment.

Obesity Market Snapshot: Marketing Partners Giving Obesity The Slow Goodbye

After two years of almost nonexistent sales, analysts are ringing the death knell for the obesity market as revenues of once-promising obesity drugs continue to decline. The expectation is that virtually all of the major marketing partners will exit their respective partnerships in the near-term and more than one player could run out of cash.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133145

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel